HOWL Werewolf Therapeutics, Inc.
-
Werewolf Therapeutics Reported Earnings
Friday, November 13, 2026 · 12:00 AM ET
Werewolf Therapeutics (HOWL) reported a loss of $0.20 per share on revenue of $0.00 million for the third quarter ended September 2026. .
Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.20)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—